Medication-related osteonecrosis of the jaws associated with intravitreal administration of ranibizumab. Issue 12 (December 2020)

• Record Type: Journal Article
• Authors: Oz, I.; Kaplan, I.; Kleinman, S.; Arbel, S.; Shuster, A.
• Is Part Of: International journal of oral & maxillofacial surgery. Volume 49:Issue 12(2020:Dec.)
• Page Start: 1589
• Page End: 1591
• Publication Date: 2020-12
• Subjects: MRONJ -- Anti-angiogenic agent -- Ranibizumab; Mouth -- Surgery -- Periodicals; Maxilla -- Surgery -- Periodicals; Dentistry -- Periodicals; Dentistry, Operative; Oral Surgical Procedures; Surgery, Oral; Dentistry; Maxilla -- Surgery; Mouth -- Surgery; Electronic journals; Periodicals; 617.52059
• DOI: 10.1016/j.ijom.2020.05.017
• Languages: English
• ISSNs: 0901-5027

Abstract

Abstract: Medication-related osteonecrosis of the jaws (MRONJ) is a well-known complication that, in the majority of cases, is related to antiresorptive agents. Numerous articles have described cases of MRONJ in bisphosphonate-naïve patients treated with anti-angiogenic agents administered via various routes. A single case of MRONJ after intravitreal injection of bevacizumab has been reported. We report a case of MRONJ after intravitreal injection of a different anti-angiogenic agent – ranibizumab – for the treatment of neovascular age-related macular degeneration, in a bisphosphonate-naïve patient. Although it may be a rare complication, patients treated with multiple doses of anti-angiogenic agents should be monitored for the possible early diagnosis of MRONJ.